Ocrevus Use Still Growing in Europe But Challenges on Horizon, Spherix Reports

From: Multiple Sclerosis News Today

By: Marta Figueiredo

Prescriptions of Roche’s Ocrevus (ocrelizumab) among multiple sclerosis (MS) patients initiating or switching a disease-modifying therapy (DMT) continue to rise in Europe, according to a survey conducted by Spherix Global Insights…(read more)